arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Korro Bio, Inc.

KRRO
$9.82 ▼ -0.54 (-5.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
25 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Korro Bio, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $173.0M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC None
FCF / Share $-0.97 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-19.62M
↑ +16.1% —
Operating Margin Operating profit as % of sales
-185.7%
↑ +57.3% —
FCF / Share Free cash flow per share
$-0.97
↑ +30.3% —
Long-Term Debt Long-term obligations
$180.00K
↓ -18.9% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.67x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters